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Professor Saikku: I propose to divide the discussion 
into three parts, first, diagnostic aspects, second, cardio- 
vascular aspects, and third, respiratory aspects. 
DIAGNOSTIC ASPECTS 
Question: We have heard that infection by Chlamydia 
pneumoniae in the respiratory tract will increase the 
colonization of pathogens. But what kind of pathogens: 
intracellular pathogens or others? 
Professor Saikku: You find two kinds of association: 
one with intracellular pathogens and another with 
pathogens such as those involved in acute pneumonia. 
But I must emphasize that such associations are reported 
particularly with serology. 
Comment: We have data showing that C. pneumoniae 
could induce a higher susceptibility to infection. I think 
that C. pneumoniae can induce a lesion of epithelial cells 
with a disruption of the mucociliary system, producing 
a more favorable environment for other pathogens. 
This may be involved, at least in part, in the chronic 
inflammation that is present in chronic bronchitis and 
probably in asthma. 
Question: Do you also see any association with fungal 
iiifection of the lung such as Aspetgillus? 
Professor Saikku: No, we do not. 
Dr RodlufE In producing data for MIC both on 
roxithromycin and doxycycline, how long do you 
incubate? 
Professor Orfila: We infected the cells with C. pneu- 
nioniae and after 3 h we washed the cells and put the 
medium with antibiotic. We did the subculture to 
determine the MBC and it was just one dilution higher. 
Professor Mayaud: Thank you for the critical evalua- 
tion of the diagnosis of C. pneumoniae infection that 
Professor Saikku gave us. I think it is important to stress 
that there are different definitions of positivity accord- 
ing to titers. One report may regard more than 1:64 to 
be positive, the next 1:128 as positive, or 1256 as 
positive. We should also keep in mind that there are 
patients who have high titers against C. pneumoniae, 
who have no infection. I think it is also important to 
stress that the P C R  results depend on the method used. 
There are some studies using P C R  which do not find 
positive results in these atherosclerotic lesions and other 
groups find about 30-40% positive results. This should 
remind us of the difficulties in diagnosing this chronic 
infection. 
Question: If we have a suspicion of acute or chronic 
C. pneumoniae infection, what further investigation 
would you choose? 
Professor Saikku: At present the only way to 
differentiate between acute and chronic C. pneumoniae 
infection relates to seroconversion. At this moment this 
is the gold standard for acute C. pneumoniae infection. 
You cannot deduce it from titers, even IgM titers, 
although they are strongly suggestive. They depend on 
the antigen used and other factors. You cannot give 
exact numbers and you should make standards in your 
own laboratory testing normal serum. 
CARDIOVASCULAR ASPECTS 
Dr Lorenz: I have two questions for Dr Gurfinkel. 
The first is, did you analyze other prognostic factors 
within this half-year period, for instance arterial hyper- 
tension or hypercholesterolemia? The second is, why 
were you so tolerant regarding the total dose of the 
antibiotic? 
Dr Gurfinkel: We do not know how long we have to 
treat these patients before we eliminate the pathogens. 
Perhaps Professor Campbell can answer this question in 
the future. But 3 days is not long in my view. At the 
moment, in the cardiovascular field the most important 
risk factor prognosis markers are C-factor protein, 
tropalin T and tropalin I. No differences could be 
found in the groups in respect to these markers, because 
the patients were very well balanced. There was a trend 
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suggesting that the patients in the roxithromycin group 
were in the highest risk group but it did not reach 
statistical significance. 
The second question is very important but I think 
it is quite difficult to answer. We decided to analyze the 
data for a minimum period of 2-3 days in place of 
4, in accordance with a recommendation given by the 
FDA. To analyze patients with unstable angina the 
minimum is 3 days for anticoagulant drugs or any other 
new intervention. We adapted this study for a mini- 
mum period of 3 days and a maximum of 30 days, but 
we have not enough information how long we have to 
use the drug. We will have to resolve this in the near 
future. 
Question: I wonder if Dr Gurfinkel could tell us a bit 
more about the ST segment monitoring. Was it your 
conclusion that there was no change in this parameter? 
Dr Gurfinkel: We analyzed the estimated lesion at the 
monient of admission. Obviously, this is a multicenter 
trial and we have no opportunity to analyze in all the 
patients who show ST segment elevation. One of the 
clinical inclusion criteria was angina plus ST segment 
elevation but we cannot monitor this in all of the 
patients because it was a multicenter study at eight sites. 
Dr Leinonen: I would like to ask Professor Campbell 
one question. In Finland we have been using C. 
prieumoniae animal models as well. We have used 
different C. pneumoniar strains and we have found that 
there are some differences in the virulence of different 
C. pneunzor~iae strains in our mouse model. Do  you have 
any experience on the use of different C. pneumoniae 
strains in the apoE-deficient mice? 
Professor Campbell: No, unfortunately we do not. 
Dr Leinonen: But might some of the strains be more 
cardiophilic, for instance? 
Professor Campbell: I really cannot answer that 
because we do not have any experience. We do not see 
any difference in in vitro tests. 
Dr Graham: Dr Gurfinkel alluded to a potential role 
for the presence of HLA D R 4  as permissive for the 
development of coronary artery disease in people 
infected with Chlamydia. What is the evidence for the 
role of an HLA association, particularly HLA DR4? 
D r  Gurfinkel: We published this evidence in the 
Journal of Cardiology and now it is in Circulation [l]. We 
performed two analyses, the D R  B4 and the DK A28, 
but we must repeat these analyses in other sorts of 
patients. We suggested that the locus is the DR I34 but 
obviously this is speculation and we need more infor- 
mation. We are trying to reproduce this information in 
the Roxis study [2].  
RESPIRATORY DISEASE 
Professor Mayaud: I have a question for Dr Blasi and 
Professor Saikku. In animal models, when you give 
steroids you have an increased replication of C. pnerr- 
moniae. Do you think in asthmatic patients there is 
a similar role for steroids to cause replication of C. 
pneumoniae? 
Dr Blasi: Patients with severe chronic obstructive pul- 
monary disease (COPD) who use more steroids seem 
to have a higher prevalence of C. pneurnoniae. We have 
about 25% of chronic cases of C. pneumoniae, but I have 
no data on the use of steroids. If it is confirmed that 
severe COPD patients have a higher prevalence of 
carriage of C. pneurnorziac, it could be due to the higher 
use of inhaled steroids. 
Professor Saikku: We have not done these types of 
studies but I can quote Dr Hahn, who has had difficulties 
in isolating C. pneurnoniae from asthmatic patients. Of  
course, it is difficult in chronic infections. But if they 
are treated with cortisone, then he can be successful 
every now and then. 
Question: Is there any asPociation between Myroplasma 
pneumoniae or C. pneumoniae and acute exacerbations in 
cystic fibrosis patients, particularly those refractory to 
standard antibiotic therapy? 
Professor Mayaud: In children with cystic fibrosis, 
one study found C. pncuuzoniae only in those children 
with exacerbation and not in controls [3]. However, it 
was just a preliminary investigation. 
I have a last question for Dr Blasi. I was very 
interested by your study in patients with COPD and 
with positive or negative P C R  [4]. Was there any 
difference in bronchial reactivity between the two 
groups? 
Dr Blasi: There was no difference in pulmonary func- 
tion. However, there were only 35 patients and only 
nine patients with C. pneumoniae. 
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Professor Saikku and Professor Mayaud: In 
conclusion, this session has concentrated on a major 
advance in medical science comparable to the 
Australian discovery of links between Helicobacter pylori 
and peptic ulcer. An agent which was originally 
thought to be the minor respiratory tract pathogen is 
slowly being revealed to be associated with diseases of 
utmost importance. It seems to have found its own 
place among the other intracellular pathogens causing 
acute respiratory infections. But according to recent 
findings, Chlamydia pneumoniae seems to be a prime 
candidate among intracellular pathogens associated 
with chronic diseases. We have heard about its 
association with asthma, and its ability to multiply in 
target cells or atherosclerotic lesions, and impressive 
animal models have been developed. 
It now remains only for me to thank the speakers, 
the audience and, of course, our Sponsors, Hoechst 
Marion Roussel, for this exciting and thought- 
provoking event. 
